Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

2,357 recalls · Class II, newest first

Class II · Moderate risk

All Over-The-Counter

CGMP Deviations: Potential exposure to rodents and rodent activity in the distribution center.

Ongoing cGMP deviation Dollar Tree Distribution, Inc. D-0641-2022
Class II · Moderate risk

Methylphenidate Hydrochloride Chewable Tablets

Failed Tablet Specifications: Recall of this drug product was voluntarily initiated by the manufacturer due to a market complaint, which stated that a tablet in the sealed bottle was twice larger in size when compared to the remaining tablets. This complaint is second of its kind.

Ongoing Failed specification Rising Pharmaceuticals NDC 64980-221-01 D-0573-2022
Class II · Moderate risk

Lexette (halobetasol propionate)

CGMP Deviation: Difficulty dispensing/does not dispense or dispensing liquid instead of foam.

Ongoing cGMP deviation Mayne Pharma Inc NDC 51862-604-50 D-0387-2022
Class II · Moderate risk

Diclofenac Sodium Topical Solution

Defective container: Out of specification for container integrity leading to bottles leaking.

Ongoing Packaging defect Preferred Pharmaceuticals, Inc. NDC 68788-7707-01 D-0278-2022
Class II · Moderate risk

The Natural Dentist Healthy Balance Peppermint Sage

Labeling; Label mix-up and Wrong Bar Code; back label incorrectly states active ingredient as Menthol with UPC 7 14132 00071 4 instead of Peppermint Oil and Sage Oil with UPC 7 14132 00073 8

Ongoing Labeling / mix-up Revive Personal Products Company D-0364-2022
Class II · Moderate risk

Chantix (varenicline)

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

Ongoing Nitrosamine impurity Pfizer Inc. NDC 0069-0469-03 D-0811-2021
Class II · Moderate risk

Chantix (varenicline)

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

Ongoing Nitrosamine impurity Pfizer Inc. NDC 0069-0469-56 D-0810-2021
Class II · Moderate risk

Chantix (varenicline)

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

Ongoing Nitrosamine impurity Pfizer Inc. NDC 0069-0468-56 D-0809-2021
Class II · Moderate risk

Chantix (varenicline)

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

Ongoing Nitrosamine impurity Pfizer Inc. NDC 00069-0471-03 D-0808-2021
Class II · Moderate risk

Combipatch

Failed Stability Specifications; out of specification for shear.

Ongoing Stability / shelf life Noven Pharmaceuticals Inc NDC 68968-0525-2 D-0725-2021
Class II · Moderate risk

Combipatch

Failed Stability Specifications; out of specification for shear.

Ongoing Stability / shelf life Noven Pharmaceuticals Inc NDC 68968-0514-2 D-0724-2021

Recalls by year